|
Tue, 08/12/2025 - 06:33 |
Mumbai, August 12, 2025: Global Pharma major Lupin Limited (Lupin) today announced that it has partnered with Sandoz Group AG (Sandoz), Switzerland, to market and commercialize Lupins biosimilar ranibizumab across multiple regions. |
Lupin |
|
Wed, 01/02/2019 - 05:34 |
Momenta Pharmaceuticals to Webcast Presentation at the 37th Annual J.P. Morgan Healthcare Conference |
Momenta |
|
Wed, 12/19/2018 - 02:36 |
Sandoz enters into commercialization and supply agreement for insulin biosimilars, anticipating growing demand as diabetes burden rises |
Novartis |
|
Tue, 12/11/2018 - 07:07 |
Momenta Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares |
Momenta |
|
Thu, 12/06/2018 - 06:37 |
UPDATE: Momenta Pharmaceuticals Announces Pricing of Public Offering of Common Stock |
Momenta |
|
Wed, 12/05/2018 - 07:20 |
Momenta Pharmaceuticals Announces Proposed Public Offering of Common Stock |
Momenta |
|
Mon, 12/03/2018 - 14:59 |
CASI Pharmaceuticals Announces China Market Approval Of Melphalan Hydrochloride For Injection (Trademark: EVOMELA) |
CASI Pharmaceuticals |
|
Mon, 12/03/2018 - 05:41 |
Momenta Pharmaceuticals Provides Update on US Regulatory Strategy for M923, Proposed Biosimilar to HUMIRA |
Momenta |
|
Thu, 11/29/2018 - 17:42 |
Novartis announces EU approval of Gilenya for children and adolescents with MS, making it the first and only oral disease-modifying treatment for these patients in Europe |
Novartis |
|
Wed, 11/28/2018 - 16:18 |
FDA approves first biosimilar for treatment of adult patients with non-Hodgkins lymphoma |
FDA |
|
Tue, 11/27/2018 - 12:51 |
Sandoz receives eighth European Commission approval for a biosimilar with Ziextenzo (pegfilgrastim) |
Novartis |
|
Tue, 11/20/2018 - 18:32 |
Sandoz and Pear Therapeutics announce launch of reSET for treatment of patients with Substance Use Disorder |
Novartis |
|
Fri, 11/16/2018 - 14:16 |
CASI Pharmaceuticals To Build GMP Manufacturing Site In Wuxi, China |
CASI Pharmaceuticals |
|
Thu, 11/08/2018 - 19:10 |
Paralyzed Veterans of America announces winners of 2018 Veterans Day National Poster and Poem Contest |
PVA |
|
Wed, 11/07/2018 - 05:36 |
Momenta Pharmaceuticals Announces Publication of Phase 1 Study Data for Anti-FcRn Antibody, M281 |
Momenta |
|
Tue, 11/06/2018 - 05:53 |
Momenta Pharmaceuticals Announces Global Settlement with AbbVie to Enable Commercialization of M923, a Proposed Biosimilar to HUMIRA (adalimumab) |
Momenta |
|
Tue, 11/06/2018 - 05:18 |
Momenta Pharmaceuticals to Webcast Presentation at the Stifel 2018 Healthcare Conference |
Momenta |
|
Fri, 11/02/2018 - 00:01 |
Sandoz decides not to pursue US biosimilar rituximab; will focus on robust biosimilar portfolio for unmet access and sustainability needs |
Novartis |
|
Thu, 11/01/2018 - 22:57 |
Novartis data at ASH and SABCS show strength of pipeline and portfolio in hematology and oncology |
Novartis |
|
Wed, 10/31/2018 - 07:38 |
Sandoz receives US FDA approval for biosimilar Hyrimoz(TM) (adalimumab-adaz) |
Novartis |
|
Wed, 10/24/2018 - 13:56 |
Salk mourns the passing of immunology titan Melvin Cohn, PhD, founding fellow of the Salk Institute and a pioneer in the field of gene regulation |
Salk Institute |
|
Thu, 10/11/2018 - 20:51 |
Breadth of data at ECTRIMS underpins Novartis' relentless commitment to decoding the science of multiple sclerosis (MS) and decreasing the patient burden |
Novartis |
|
Thu, 10/11/2018 - 07:33 |
Momenta Pharmaceuticals to Host R&D Day on October 11, 2018 |
Momenta |
|
Wed, 10/10/2018 - 21:29 |
Sandoz announces global resolution of biosimilar adalimumab patent disputes, securing patient access |
Novartis |
|
Tue, 10/09/2018 - 21:14 |
Novartis announces new data from the first direct head-to-head trial to demonstrate superior efficacy of Gilenya over Copaxone in patients with relapsing remitting multiple sclerosis |
Novartis |
